The Italy Diabetes Care Devices Market size is estimated at USD 0.92 billion in 2023, and is expected to reach USD 1.27 billion by 2028, growing at a CAGR of 6.70% during the forecast period (2023-2028).
Within the first year since its inception, the COVID-19 pandemic has been responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy is among the countries with the highest excess mortality. Most people who have died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.
The COVID-19 pandemic has significantly impacted Italy's diabetes care devices. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market's growth.
About 9.9% of the Italian population has diabetes as of 2021. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device includes a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. CGM makes it significantly easier to manage blood glucose levels by decreasing interruptions and allowing for better sleep. It also improves the mental health of patients or caregivers by reducing the overall mental load of managing diabetes, thereby enhancing the market prospects in the coming years.
The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. These technologies overcome many limitations of self-monitoring blood glucose by fingerprick and allow one to go beyond HbA1c to check glucose control in diabetes. Furthermore, the technological advancements in continuous glucose monitoring sensors opened new scenarios to assess, off-line, the effectiveness of individual patient therapeutic plans and stimulated the development of innovative online applications. It includes hypoglycemia or hyperglycemia alert systems and artificial pancreas closed-loop control algorithms.
The Italian National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes can access all the medicines, devices, and medical services they need with no out-of-pocket expenditure. Overall, Italy includes a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery.
The factors above are likely to drive segment growth during the forecast period.
A disposable insulin pen contains a prefilled amount of insulin. When the pen is empty, it is thrown away. Insulin pens are much smaller, more portable than syringes, and contain the medicine preloaded into the delivery mechanism. The needles are easy to use and can be disposed of by twisting or snapping. The pens are usually color-coded, making it easier to know which type and how much insulin will be received from them. The disposable insulin pens are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers. Some pens are smart insulin pens that easily connect to an app on the phone to monitor blood sugar levels and remind when to take the next insulin dose.
Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions, based on a patient's income. The Insulin pens are free for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.
Technological development is gaining momentum in the insulin devices market. Several technological innovations were developed over many years, creating new types of devices that are much less cumbersome and more comfortable for patients than traditional ones. Such advantages helped increase these products' adoption in the Italian market.
Within the first year since its inception, the COVID-19 pandemic has been responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy is among the countries with the highest excess mortality. Most people who have died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.
The COVID-19 pandemic has significantly impacted Italy's diabetes care devices. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market's growth.
About 9.9% of the Italian population has diabetes as of 2021. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Italy Diabetes Care Devices Market Trends
The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period
The continuous glucose monitoring segment is expected to record a CAGR of more than 10.8% over the forecast period.Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device includes a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. CGM makes it significantly easier to manage blood glucose levels by decreasing interruptions and allowing for better sleep. It also improves the mental health of patients or caregivers by reducing the overall mental load of managing diabetes, thereby enhancing the market prospects in the coming years.
The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. These technologies overcome many limitations of self-monitoring blood glucose by fingerprick and allow one to go beyond HbA1c to check glucose control in diabetes. Furthermore, the technological advancements in continuous glucose monitoring sensors opened new scenarios to assess, off-line, the effectiveness of individual patient therapeutic plans and stimulated the development of innovative online applications. It includes hypoglycemia or hyperglycemia alert systems and artificial pancreas closed-loop control algorithms.
The Italian National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes can access all the medicines, devices, and medical services they need with no out-of-pocket expenditure. Overall, Italy includes a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery.
The factors above are likely to drive segment growth during the forecast period.
Insulin disposable pens occupied the highest share in the management devices segment in the current year
Insulin Disposable pens occupied the highest market share of more than 43% in the management devices segment in the current year.A disposable insulin pen contains a prefilled amount of insulin. When the pen is empty, it is thrown away. Insulin pens are much smaller, more portable than syringes, and contain the medicine preloaded into the delivery mechanism. The needles are easy to use and can be disposed of by twisting or snapping. The pens are usually color-coded, making it easier to know which type and how much insulin will be received from them. The disposable insulin pens are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers. Some pens are smart insulin pens that easily connect to an app on the phone to monitor blood sugar levels and remind when to take the next insulin dose.
Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions, based on a patient's income. The Insulin pens are free for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.
Technological development is gaining momentum in the insulin devices market. Several technological innovations were developed over many years, creating new types of devices that are much less cumbersome and more comfortable for patients than traditional ones. Such advantages helped increase these products' adoption in the Italian market.
Italy Diabetes Care Devices Industry Overview
The Italian diabetes care devices market is moderately fragmented, driven by manufacturers like Roche, Abbott, Novo Nordisk, Dexcom, Medtronic, etc., and other generic players.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 Market Segmentation
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Roche Diabetes Care
- LifeScan Inc.
- Dexcom
- Medtronic
- Arkray Inc.
- Ascensia Diabetes Care
- Novo Nordisk A/S
- Eli Lilly
- Sanofi
- Insulet Corporation
- Rossmax International Ltd.
Methodology
LOADING...
